Novel Drug Delivery System To Enhance The Release Of Drug With Narrow Absorption Window

Abstract

The project aims towards development of a sustained release film to minimize the frequency of dosing and to enhance the efficacy of the drug with narrow absorption window. These drugs that are absorbed from a specific region (most notably first part) of the gastrointestinal tract. The drugs such as acyclovir gets absorbed in the upper tract of GI. The purpose of a sustained release dosage form is to keep therapeutic medication levels in the blood or tissues for a longer length of time. Attempting to acquire zero order release from the dose form is typically the way to go. Floating system is not feasible for those drugs that have solubility problems in gastric fluids. Drugs that are not stable at gastric pH are not suitable candidates to be formulated as NDDS. Drugs that irritate the mucosa. The drugs, which have multiple absorption sites in the gastrointestinal tract and are absorbed throughout gastrointestinal tract, which under significant first pass metabolism, are not desirable. Development of sustained release film possessing gastric retention capabilities. To achieve more predictable and increased bioavailability, Reduction in dosing frequency, reduced fluctuation in circulating drug levels, increased patient compliance, avoidance of night time dosing, more uniform effect and reduction in gastrointestinal (GI) irritation and other dose-related side effects. It can be concluded that the film enclosed in a capsule will swell and remain mucoadhesive in the GI and release APIs over a period of 12 hours there by increasing the bioavailability of Acyclovir and dexamethasone